Cargando…
Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor
Despite neurosurgery following radiation and chemotherapy, residual glioblastoma (GBM) cells develop therapeutic resistance (TR) leading to recurrence. The GBM heterogeneity confers TR. Therefore, an effective strategy must target cancer stem cells (CSCs) and other malignant cancer cells. TGF-β and...
Autores principales: | Liu, Chan-Chuan, Wu, Cheng-Lin, Lin, Meng-Xuan, Sze, Chun-I, Gean, Po-Wu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508702/ https://www.ncbi.nlm.nih.gov/pubmed/34638842 http://dx.doi.org/10.3390/ijms221910496 |
Ejemplares similares
-
Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023) -
High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells
por: Hothi, Parvinder, et al.
Publicado: (2012) -
Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells
por: Chang, Chia-Hsin, et al.
Publicado: (2017) -
The Combination of Metformin and Disulfiram-Cu for Effective
Radiosensitization on Glioblastoma Cells
por: Rezaei, Narges, et al.
Publicado: (2020) -
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
por: Zirjacks, Lisa, et al.
Publicado: (2021)